Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
NCT05704647
Recruiting
To learn if giving nivolumab in combination with relatlimab can help to control melanoma that has spread to the brain (melanoma with brain metastases). The safety and side effects of the study drug combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Melanoma (Skin)
Register for Updates
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
NCT05849298
Recruiting
The purpose of this study is to evaluate the efficacy and safety of AAA617 alone (Lutetium \[177Lu\] vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in participants with PSMA-positive, castration-resistant prostate cancer and no evidence of metastasis in conventional imaging (CI) (i.e., CT/MRI and bone scans). Approximately 120 participants will be randomized.
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
04/22/2025
Locations: Urology Associates of Mobile, Mobile, Alabama +44 locations
Conditions: Prostatic Neoplasm
Register for Updates
Managing Opioid Related Sleep Apnea With Acetazolamide
NCT06043830
Recruiting
Patients with chronic pain who use opioids appear to be at increased risk for breathing issues during sleep, termed sleep disordered breathing (SDB). Treatment of SDB often consists of use of a device during sleep that provides continuous positive airway pressure (CPAP) via a mask interface. However, this device is not effective or tolerated in all individuals. The goal of this study is to examine whether a medication called acetazolamide can improve SDB, as an alternative to CPAP treatment. Th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: University of California San Diego, San Diego, California
Conditions: Sleep-Disordered Breathing, Obstructive Sleep Apnea, Central Sleep Apnea, Chronic Pain, Opioid Use
Register for Updates
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574
Recruiting
This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including chemotherapy for advanced or metastatic lung cancer. The purpose of this study is to find out whether a medicine called zongertinib (BI 1810631) can slow down the worsening of advanced non-small cell lung cancer better than the standard treatment available. Zongertinib ma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Clearview Cancer Institute, Huntsville, Alabama +168 locations
Conditions: Lung Cancer, Non-squamous, Non-small Cell
Register for Updates
Decision Support for Heart Failure Prescribing
NCT06293794
Recruiting
Clinical decision support (CDS) tools can 'nudge' clinicians to make the best decisions easy. Although required by "meaningful use" regulations, more than 40% of CDS lead to no change and the remaining lead to improvements that are modest at best. This is because CDS tools often ignore contextual factors and present irrelevant information. Although many tools have undergone patient-specific optimization, 'traditional CDS' are rarely clinician-specific. For example, a traditional CDS tool for bet... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
04/22/2025
Locations: UCHealth Primary Care and Cardiology Outpatient Clinics, Aurora, Colorado
Conditions: Decision Support Systems, Clinical, Heart Failure
Register for Updates
Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder
NCT06384157
Recruiting
The purpose of this study is to measure safety and efficacy and to determine dose-response relationship for INDV-2000 in participants with moderate to severe Opioid Use Disorder (OUD) who are new to treatment, have recently initiated or completed short-term medically supervised withdrawal with transmucosal (TM) buprenorphine, and are interested in transitioning to a non opioid treatment.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/22/2025
Locations: Boyett Health Services Inc, Hamilton, Alabama +34 locations
Conditions: Opioid Use Disorder
Register for Updates
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
NCT06496178
Recruiting
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Site 102, Prescott, Arizona +115 locations
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial
NCT06605118
Recruiting
This is a phase-III multi-center double-blind randomized controlled trial of 8,000 individuals undergoing a scheduled or prelabor cesarean delivery who are randomized to either adjunctive azithromycin prophylaxis or to placebo. Both groups also will receive standard of care preoperative antibiotics (excluding azithromycin). The primary endpoint is a maternal infection composite defined as any one of the following up to 6 weeks postpartum: endometritis, wound infection, abscess, septic thrombosis... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
04/22/2025
Locations: University of Alabama - Birmingham, Birmingham, Alabama +13 locations
Conditions: Obstetrical Complications, Labor and Delivery Complication, Cesarean Delivery
Register for Updates
A Randomized Crossover Trial of Bright Light Therapy in Irritable Bowel Syndrome
NCT06676488
Recruiting
The purpose of this research study is to assess whether morning bright light therapy (BLT) using a wearable device called a Re-Timer could potentially improve Irritable Bowel Syndrome (IBS) symptoms and decrease intestinal permeability (leaky gut). Morning bright light therapy will be administrated through a safe-wearable glasses device called a Re-Timer. The Re-Timer glasses are lightweight and deliver blue-green light at 500nm, mimicking exposure to natural light.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/22/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Irritable Bowel Syndrome (IBS), Circadian Misalignment
Register for Updates
Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
NCT06782542
Recruiting
The purpose of this study is as follows: 1. Determine whether people receiving the combination treatment of olutasidenib, venetoclax, and azacitidine have the same, more, or fewer side effects compared to the usual chemotherapy treatment that people with this condition receive. 2. Determine how well the combination treatment of olutasidenib, venetoclax, and azacitidine works compared to the usual chemotherapy treatment that people with this condition receive.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/22/2025
Locations: University of Miami, Miami, Florida
Conditions: Acute Myeloid Leukemia, IDH1 Mutation
Register for Updates
Lemborexant in Delayed Sleep Phase Syndrome
NCT06874855
Recruiting
The purpose of the study is to evaluate whether Lemborexant is more effective than placebo in shortening sleep onset latency in patients with delayed sleep phase syndrome (both type 1 and type 2). This will be tracked using sleep logs as well as actigraphy. In this 2-year study, the investigators will examine if Lemborexant administered 5-10 mg nightly taken at desired bedtime (at least 2 hours prior to self-reported sleep onset habitual time) can improve the symptoms of Delayed Sleep Phase Syn... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: University of California San Francisco, San Francisco, California
Conditions: Delayed Sleep Phase Syndrome
Register for Updates
Clinical Research Evaluating Smoking Cessation With E-Cigarettes and Nicotine Therapy
NCT06948058
Recruiting
This project will investigate the effects of alternative nicotine products on smoking, weight gain, and related outcomes.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/22/2025
Locations: Brown University, Providence, Rhode Island
Conditions: Smoking Cessation, Obesity and Obesity-related Medical Conditions
Register for Updates